Beth Bretz
Family · New Stanton, PANPI 1376969600
Payments from drug & device makers
Across 475 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Lilly USA, LLC$629
- AstraZeneca$588
- Pfizer$470
- Bayer$325
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,54299%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 139 | $1,454 |
| Novo Nordisk | 87 | $1,444 |
| Lilly USA, LLC | 33 | $629 |
| AstraZeneca | 30 | $588 |
| Pfizer | 28 | $470 |
| Bayer | 15 | $325 |
| Xeris Pharmaceuticals, Inc. | 14 | $292 |
| Otsuka America Pharmaceutical, Inc. | 10 | $284 |
| Exact Sciences | 19 | $244 |
| Johnson & Johnson | 11 | $225 |
| Abbott | 12 | $224 |
| GSK | 13 | $214 |
| Astellas Pharma US Inc | 7 | $190 |
| Merck | 8 | $159 |
| Aimmune Therapeutics, Inc. | 6 | $116 |
| UCB, Inc. | 4 | $82 |
| E.r. Squibb & Sons, L.L.C. | 5 | $80 |
| Kowa Pharmaceuticals America, Inc. | 5 | $79 |
| Currax Pharmaceuticals LLC | 4 | $61 |
| Neurelis, Inc. | 2 | $60 |
| Dexcom, Inc. | 4 | $56 |
| Novartis | 3 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Boehringer Ingelheim | 1 | $28 |
| Acadia Pharmaceuticals Inc | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Boston Scientific | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Orexo US, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,642 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 136 | $101,092 |
| OzempicSemaglutide | 61 | $72,400 |
| RybelsusSemaglutide | 17 | $39,417 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $24,891 |
| XareltoRivaroxaban | 34 | $22,418 |
| JanuviaSitagliptin Phosphate | 38 | $20,745 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $20,324 |
| FarxigaDapagliflozin Propanediol | 12 | $18,742 |
| TradjentaLinagliptin | 21 | $10,872 |
| Desmopressin Acetate | 17 | $8,436 |
| Fluphenazine Hcl | 13 | $8,020 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $5,981 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $5,698 |
| MyrbetriqMirabegron | 12 | $5,568 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $4,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,444 | $111,81778 claims |
| PfizerEliquis | $470 | $101,092136 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $214 | $24,95842 claims |
| Johnson & JohnsonXarelto | $225 | $22,41834 claims |
| MerckJanuvia | $159 | $20,74538 claims |
| AstraZenecaFarxiga | $588 | $18,74212 claims |
| Boehringer IngelheimTradjenta, Stiolto Respimat | $28 | $15,79632 claims |
| Astellas Pharma US IncMyrbetriq | $190 | $5,56812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in New Stanton
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.